Bevacizumab Induced Thrombotic Microangiopathy in a 71-Year Old Glioblastoma Patient

Bevacizumab is a humanized monoclonal antibody which primarily targets Vascular Endothelial Growth Factor (VEGF). Renal injury, including proteinuria and nephrotic syndrome, is a common adverse event associated with anti-VEGF therapy [1]. It has been described in patients treated for renal cell carcinoma, ovarian, breast, colon, and lung cancers [2]....